ActivePure’s Latest Technology Thwarts Nosocomial MRSA Dominance

The publication of ActivePure‘s study on Methicillin-Resistant Staphylococcus aureus (MRSA), surface microbial burden, and Healthcare-Associated Infections (HAIs) was announced on January 17, 2023. ActivePure is an infection prevention technology company that offers continuous, whole-department disinfection technology.

Clear-Cut Study Results

When compared to the same time period a year previously and the immediate six months prior, Healthcare-Onset MRSA (HO-MRSA) bacteremia infections had a statistically significant 100% drop, and in fact were eliminated over the trial period. No adjustments to the hospital’s cleaning and disinfection routines, trainings, or timetables were made or necessary once this self-operating system was adopted throughout the ICU department.

The study also found that the levels of MRSA surface burden decreased by a statistically significant 98% from baseline to the last post-activation test in a medical-surgical intensive care unit (ICU) when ActivePure’s Advanced Photocatalytic Oxidation technology was used. The paper is currently accessible here, through the Infectious Diseases Society of America’s (IDSA) publication Open Forum Infectious Diseases.

Vice President of Clinical Affairs and Medical Liaison at ActivePure Medical Caitlin Crews-Stowe, MPH, CPC, CIC, CPHQ, VA-BC, is the study’s lead author. In addition to her, Katherine Baumgarten, MD, and Nattie Leger, MSN, RN, LSSBB, are co-authors of the abstract.

Infection Prevention 101

The number one goal of infection prevention and control is to keep patients and team members safe as HAIs in healthcare continue to increase and occur. In its pursuit of public health, ActivePure Medical is still very active. The research’s co-author and Director of Infection Control at the study hospital, Lori Berthelot, RN, BSN, CIC, provided this brief statement.

Beth Ann Lambert, MS, CIC, System Director of Infection Prevention and Control for the study hospital and study co-author, added that it was an honor for her to be able to share their encounter and inspire others about finding ways to improve the climate of care despite the difficult circumstances of a pandemic and shrinking workforce crisis.

Infection hazards have recently been more visible as a result of issues that have long existed being brought to light and their visibility being increased, as well as by the availability of 21st century solutions. According to Deborah Birx, M.D., Chief Medical and Science Advisor of ActivePure Technologies, the outcomes of this study have made it possible for healthcare facilities to safeguard their areas vulnerable to the spread of infections associated with healthcare, such as MRSA, with results that have been validated in actual settings. Through thorough research and FDA approval, ActivePure Medical has devoted a lot of effort to demonstrating the technology’s effectiveness. All of this research has demonstrated that combating multidrug-resistant bacteria and fungi, such as SAR-CoV-2, that are aerosol pathogens is an urgent problem that needs to be solved right away.

Visit www.ActivePureMedical.com/MRSA to read the full study or find out more about ActivePure Medical. 

About MRSA

The term “Methicillin-Resistant Staphylococcus aureus” (MRSA) refers to a particular strain of staph bacteria that is resistant to a number of medications, including methicillin, penicillin, amoxicillin, and others. MRSA can result in bloodstream infections, pneumonia, or surgical site infections in a medical setting. MRSA is present in the nose or on the skin of about 5% of hospital patients in the US.

Increases in invasive Hospital-Onset MRSA (HO-MRSA) infections have been caused by the ongoing COVID-19 pandemic, which has also hindered reduction efforts. For MRSA (14%) between 2020 and 2021, statistically significant increases were noted.

About ActivePure

Since 1924, ActivePure, a privately held company, has led the world in active, continuous surface and air disinfection systems for use in commercial, public, and residential settings, including healthcare, education, and hospitality. Independent university and laboratory testing has demonstrated the effectiveness of the patented ActivePure Technology in reducing and neutralizing indoor pollutants. It is the only item in its category to be honored in the Space Foundation Hall of Fame and certified by the Space Foundation as Certified Space Technology.

ActivePure was included in the Inc. 5000 list of the most prosperous and rapidly expanding private businesses in America in 2022. Additionally, the ActivePure Medical Guardian has FDA Class II Medical Device registration and clearance. In order to limit exposure to pathogens, such as RNA and DNA viruses, bacteria, and molds, in the air and on surfaces, by up to 99.9%, ActivePure Technology was initially created for use in space exploration. Since then, it has evolved for application in commercial and consumer products.

Visit ActivePure.com or dial 888-217-4316 for additional details.

About ActivePure Medical, LLC

After the ActivePure Medical Guardian achieved Class II Medical Device clearance from the U.S. Food and Drug Administration (FDA), ActivePure Medical—the company’s exclusive supplier of healthcare—was established in 2020. To battle some of the most resilient microorganisms in healthcare that cause healthcare-associated infections (HAIs), ActivePure engineers created these medical-grade, automated, and continuous disinfection systems.

The ActivePure Medical units are offered in portable and induct HVAC models and have undergone comprehensive independent laboratory testing as well as challenging healthcare environments to demonstrate their efficacy. The California Air and Resource Board (CARB) has certified all ActivePure Medical units to fulfill ozone and electrical safety standards, and they are all built to be used throughout the whole institution without disrupting the continuity of treatment.

Call 800-572-6241 or visit ActivePureMedical.com for more information on ActivePure Medical.

Engr. Dex Marco Tiu Guibelondo, BS Pharm, RPh, BS CpE

Editor-in-Chief, PharmaFEATURES